reports
Raymond James Advances Asset Management and Practice Management Adviso...
Raymond James Advances Asset Management and Practice Management Advisor Support with Leadership Appointments The firm announced the appointment of both Doug Brigman to president of Asset Management Services and Michelle Lynch to senior vice president, Practice Management and Growth Consulting ST. PETERSBURG, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Raymond James is bolstering its commitment to deliver a best-in-class platform for financial advisors in support of their clients with the announcement of two leadership appointments. The firm’s holistic approach emphasizes both superior reso...
Orchid Island Capital to Announce First Quarter 2025 Results
Orchid Island Capital to Announce First Quarter 2025 Results VERO BEACH, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (NYSE:ORC) ("Orchid” or the "Company"), a real estate investment trust ("REIT"), today announced that it will release results for the first quarter of 2025 following the close of trading on the New York Stock Exchange on Thursday, April 24, 2025. Earnings Conference Call Details An earnings conference call and live audio webcast will be hosted Friday, April 25, 2025, at 10:00 AM ET. Participants can register and receive dial-in information at .A ...
The Board of Invalda INVL proposed to allocate dividends for the year ...
The Board of Invalda INVL proposed to allocate dividends for the year 2024 On 8 April 2025, the Board of Invalda INVL decided to propose to the Annual General Shareholders Meeting of the company to be held on 30 April 2025 to allocate a dividend of EUR 1.25 per share for the year 2024, when the total number of shares entitling to dividends is 12,016,791. The total amount allocated for dividends is EUR 15.02 million. The person authorized to provide additional information is:Darius Šulnis, CEO of Invalda INVL Attachment
„Invalda INVL“ valdyba siūlo skirti dividendus už 2024 m.
„Invalda INVL“ valdyba siūlo skirti dividendus už 2024 m. 2025 m. balandžio 8 d. „Invalda INVL“ valdyba priėmė sprendimą siūlyti 2025 m. balandžio 30 d. vyksiančiam eiliniam visuotiniam bendrovės akcininkų susirinkimui pritarti 1,25 EUR dividendų akcijai už 2024 m. skyrimui, kai bendras akcijų skaičius, suteikiantis teisę į dividendus, yra 12.016.791. Bendra dividendams skiriama suma, tokiu atveju, sudaro 15,02 mln. EUR. Asmuo, įgaliotas suteikti papildomą informaciją:AB „Invalda INVL“ vadovas Darius Šulnis Priedas
Draft resolutions prepared by the Board for the shareholders' meeting ...
Draft resolutions prepared by the Board for the shareholders' meeting of Invalda INVL to be held on 30/04/2025 The draft resolutions prepared by the Board of Invalda INVL (company code 121304349, registered office address Gynėjų str 14, Vilnius, Lithuania) are submitted to the Ordinary General Meeting of Shareholders to be held on 30 April 2025. The draft resolutions of the General Shareholders Meeting:1. Presentation of the public joint stock company Invalda INVL consolidated annual management report for 2024.Shareholders of the public joint stock company Invalda INVL are presented with t...
Valdybos parengti sprendimų projektai 2025-04-30 „Invalda INVL“ akcini...
Valdybos parengti sprendimų projektai 2025-04-30 „Invalda INVL“ akcininkų susirinkimui Pateikiami AB „Invalda INVL“ (įmonės kodas 121304349, buveinės adresas Gynėjų g. 14, Vilnius) valdybos parengti sprendimų projektai 2025 m. balandžio 30 d. vyksiančiam eiliniam visuotiniam akcininkų susirinkimui. Susirinkimo sprendimų projektai: 1. Supažindinimas su akcinės bendrovės „Invalda INVL“ konsoliduotąja 2024 m. metine vadovybės ataskaita.Akcininkai supažindinami su akcinės bendrovės „Invalda INVL“ konsoliduotąja 2024 m. metine vadovybės ataskaita (pridedama). Šiuo darbotvarkės klausimu sprendi...
Vicor Corporation to Hold First Quarter Earnings Conference Call and W...
Vicor Corporation to Hold First Quarter Earnings Conference Call and Webcast on April 29, 2025 ANDOVER, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Vicor Corporation (NASDAQ: VICR) announced today it will hold its first quarter 2025 earnings conference call and webcast on Tuesday, April 29, 2025 at 5:00 p.m. (Eastern). Prepared remarks regarding the company's financial and operational results for the three months ended March 31, 2025 will be followed by a question and answer period with Patrizio Vinciarelli, Chief Executive Officer, Jim Schmidt, Chief Financial Officer, and Phil Davies, Cor...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025 PORTLAND, Maine, April 08, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2025. Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the clos...
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Med...
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer Dr. Banerjee’s appointment culminates Artiva’s efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerjee, M.D., as Chief Medical Officer. D...
Mama’s Creations Reports Fourth Quarter and Fiscal Year 2025 Financial...
Mama’s Creations Reports Fourth Quarter and Fiscal Year 2025 Financial Results Fourth Quarter Revenues Increase 25.7% to $33.6 Million at 27.0% Gross Margin Profile Completion of Strategic CapEx Projects and New Senior Hires Driving Robust Revenue and Margin Growth EAST RUTHERFORD, NJ, April 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MAMA), a leading national marketer and manufacturer of fresh deli prepared foods, has reported its financial results for the fourth quarter and fiscal year ended January 31, 2025. Financial Summary: Three Months Ended Jan. 31,Fiscal Year Ended Jan. 31,$ in mi...
Kura Sushi USA Announces Fiscal Second Quarter 2025 Financial Results
Kura Sushi USA Announces Fiscal Second Quarter 2025 Financial Results IRVINE, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Kura Sushi USA, Inc. (“Kura Sushi” or the “Company”) (NASDAQ: KRUS), a technology-enabled Japanese restaurant concept, today announced financial results for the fiscal second quarter ended February 28, 2025. Fiscal Second Quarter 2025 Highlights Total sales were $64.9 million, compared to $57.3 million in the second quarter of 2024;Comparable restaurant sales decreased 5.3% for the second quarter of 2025 as compared to the second quarter of 2024;Operating loss was $4....
Annexon Highlights Pivotal Data on First Potential Targeted Therapy fo...
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS Disease Education Campaign for Healthcare Providers called Move GBS Forward™ () Highlights Life-altering Impact of GBS BRISBANE, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ANNX), a biopharmaceutical c...
Mondelēz International to Report Q1 2025 Financial Results on April 29...
Mondelēz International to Report Q1 2025 Financial Results on April 29, 2025 CHICAGO, April 08, 2025 (GLOBE NEWSWIRE) -- Mondelēz International, Inc. (Nasdaq: MDLZ) will release its first quarter 2025 financial results on Tuesday, April 29, 2025 at 4:05 p.m. ET and will host a conference call at 5:00 p.m. ET that day. Investors and analysts may participate via phone by calling 800-579-2543 from the United States and 785-424-1789 from other locations. To ensure timely access, participants should dial in approximately 10 minutes before the call starts. A listen-only webcast will be provide...
Clover Health to Report First Quarter 2025 Financial Results on May 6,...
Clover Health to Report First Quarter 2025 Financial Results on May 6, 2025 WILMINGTON, Del., April 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will report first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on May 6, 2025, to discuss Clover Health’s first quarter 2025 business and financial results. First Quarter 2025 Conference Call and Webcast Details: What: Clover Health’s Firs...
NeOnc Technologies Announces Near Completion of Phase I Enrollment for...
NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy CALABASAS, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that its Phase I clinical trial of NEO212, a development-stage bio-conjugated therapeutic for brain cancer, is nearing full enrollment. The final cohort (Cohort 5) is expected to complete the study’s dosing protocol, marking a major milestone i...
Lesaka to Host Webcast to Review Third Quarter 2025 Results
Lesaka to Host Webcast to Review Third Quarter 2025 Results JOHANNESBURG, April 08, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (NASDAQ:, JSE: LSK) ("Lesaka" or the "Company") today announced it will release third quarter 2025 results after the U.S. market close on May 7, 2025. Lesaka management will host a presentation webcast on May 8, 2025, on at 8:00am EDT (2:00pm SAST), followed by a live question and answer session for analysts and investors. Webcast Registration Link to access the results webcast: Participants using the webcast will be able to submit questions during the...
Vincerx Pharma Announces Termination of Letter of Intent and Board Aut...
Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: VINC) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global Digital Holdings Inc., conducting business as QumulusAI, regarding a potential merger. Following this decision, the Company’s board of directors has authorized management to initiate wind-down activities and continue exploring monetization of assets and out-licensing opportunities. “I want to expres...
FormFactor Introduces the EVOLVITY™ 300 Probe System
FormFactor Introduces the EVOLVITY™ 300 Probe System Company Expands the 300 mm Product Line with New Semi-Automated System LIVERMORE, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- FormFactor, Inc. (NASDAQ: FORM), a supplier of electrical test and measurement technologies, has introduced the EVOLVITY™ 300, a semi-automated engineering wafer probe system that complements the company’s proven CM300 product line. The EVOLVITY 300 simplifies on-wafer probing with its compact, easy-to-use design, developed specifically for RF/DC modeling and device characterization. While the CM300 is a modula...
Gibson Energy Confirms 2025 First Quarter Earnings Release and Annual ...
Gibson Energy Confirms 2025 First Quarter Earnings Release and Annual General Meeting Dates and Provides Conference Call & Webcast Details CALGARY, Alberta, April 08, 2025 (GLOBE NEWSWIRE) -- Gibson Energy Inc. (“Gibson” or the “Company”) announced today that it expects to release its 2025 first quarter financial and operating results on Monday, May 5, 2025, after the close of North American markets. The 2025 first quarter management's discussion and analysis and unaudited consolidated financial statements will be available on the Company's website at and on SEDAR+ at . Earnings Confe...
Nurix Therapeutics Reports First Quarter 2025 Financial Results and Pr...
Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update NX-5948 assigned the nonproprietary name “bexobrutideg”U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M license extension fee from ongoing collaboration with SanofiEnhanced oversight and leadership team with the appointments of Roy D. Baynes to the Board and John Northcott as chief commercial officerWell capitalized with cash and marketable securities of $549.7 million SAN FRANCISCO, April 08, 2025 ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.